Summary

DelveInsight’s,”Retinoic Acid Receptors Gamma (RARs) Agonists-Pipeline Insights, 2014″, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Retinoic Acid Receptors Gamma (RARs) Agonists. This report provides information on the therapeutic development based on the Retinoic Acid Receptors Gamma (RARs) Agonists dealing with mechanism of action, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.

Data Sources

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

Please note: this report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated mechanism of action.

Scope

• The report provides a snapshot of the global therapeutic landscape of Retinoic Acid Receptors Gamma (RARs) Agonists
• The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
• Coverage of the Retinoic Acid Receptors Gamma (RARs) Agonists pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
• The report reviews key players involved in the therapeutics development for Retinoic Acid Receptors Gamma (RARs) Agonists and also provide company profiling
• The report also gives the information of dormant and discontinued pipeline projects
• Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Reasons to buy

• Complete MOA intelligence and complete understanding over therapeutics development for Retinoic Acid Receptors Gamma (RARs) Agonists
• Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
• Devise corrective measures for pipeline projects by understanding Retinoic Acid Receptors Gamma (RARs) Agonists pipeline depth and focus of Indication therapeutics
• Developing strategic initiatives to support your drug development activities.
• Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
• Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
• Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions

Table of Contents

Retinoic Acid Receptors Gamma (RARs) Agonists Overview
Retinoic Acid Receptors Gamma (RARs) Agonists Disease Associated
Retinoic Acid Receptors Gamma (RARs) Agonists Pipeline Therapeutics
Retinoic Acid Receptors Gamma (RARs) Agonists Therapeutics under Development by Companies
Retinoic Acid Receptors Gamma (RARs) Agonists Late Stage Products (Filed and Phase III)
Comparative Analysis
Retinoic Acid Receptors Gamma (RARs) Agonists Mid Clinical Stage Products (Phase II)
Comparative Analysis
Retinoic Acid Receptors Gamma (RARs) Agonists Early Clinical Stage Products (Phase I and IND Filed)
Comparative Analysis
Retinoic Acid Receptors Gamma (RARs) Agonists Discovery and Pre-Clinical Stage Products
Comparative Analysis
Drug Candidate Profiles
Retinoic Acid Receptors Gamma (RARs) Agonists - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Retinoic Acid Receptors Gamma (RARs) Agonists - Discontinued Products
Retinoic Acid Receptors Gamma (RARs) Agonists - Dormant Products
Companies Involved in Therapeutics Development for Retinoic Acid Receptors Gamma (RARs) Agonists
Appendix
Methodology
Contact Us
Disclaimer

List of Tables

Number of Products under Development for Retinoic Acid Receptors Gamma (RARs) Agonists by Therapy Area, 2014
Number of Products under Development for Retinoic Acid Receptors Gamma (RARs) Agonists, 2014
Number of Products under Development by Companies
Comparative Analysis by Late Clinical Stage Products (Filed and Phase III), 2014
Comparative Analysis Mid Clinical Stage Products (Phase II), 2014
Comparative Analysis Early Clinical Stage Products (Phase I and IND Filed), 2014
Comparative Analysis Discovery and Pre-Clinical Stage Products, 2014
Drug Candidates Profiles
Retinoic Acid Receptors Gamma (RARs) Agonists Assessment by Monotherapy Products
Retinoic Acid Receptors Gamma (RARs) Agonists Assessment by Combination Products
Retinoic Acid Receptors Gamma (RARs) Agonists Assessment by Route of Administration
Retinoic Acid Receptors Gamma (RARs) Agonists Assessment by Stage and Route of Administration
Retinoic Acid Receptors Gamma (RARs) Agonists Assessment by Molecule Type
Retinoic Acid Receptors Gamma (RARs) Agonists Assessment by Stage and Molecule Type
Retinoic Acid Receptors Gamma (RARs) Agonists Therapeutics - Discontinued Products
Retinoic Acid Receptors Gamma (RARs) Agonists Therapeutics - Dormant Products
Products under Development by Companies, 2014

List of Figures

Number of Products under Development for Retinoic Acid Receptors Gamma (RARs) Agonists by Therapy Area, 2014
Number of Products under Development for Retinoic Acid Receptors Gamma (RARs) Agonists, 2014
Late Clinical Stage Products (Filed and Phase III), 2014
Mid Clinical Stage Products (Phase II), 2014
Early Clinical Stage Products (Phase I and IND Filed), 2014
Discovery and Pre-Clinical Stage Products, 2014
Retinoic Acid Receptors Gamma (RARs) Agonists Assessment by Monotherapy Products
Retinoic Acid Receptors Gamma (RARs) Agonists Assessment by Combination Products
Retinoic Acid Receptors Gamma (RARs) Agonists Assessment by Route of Administration
Retinoic Acid Receptors Gamma (RARs) Agonists Assessment by Stage and Route of Administration
Retinoic Acid Receptors Gamma (RARs) Agonists Assessment by Molecule Type
Retinoic Acid Receptors Gamma (RARs) Agonists Assessment by Stage and Molecule Type